Preview Newsletter
XARELTO Media Monitoring – Week of 5-27-16
-
Widow Files Xarelto Bleeding Lawsuit After Husbands Death
May 25, 2016 | Banville Law
TheProductLawyers.com reports on the death of a Xarelto user who suffered a subdural hemorrhage due to uncontrollable internal bleeding that doctors were unable to stop. His widow alleges the fatal bleed was caused by taking Xarelto, a blood-thinning drug manufactured by Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer Healthcare. -
Xarelto Lawsuit Plaintiff Claims Drug Manufacturers Responsible For Husbands Death
May 24, 2016 | Banville Law
TheProductLawyers.com reports the U.S. Food and Drug Administration (FDA) approval of Xarelto in 2011, which at the time was launched as a new-generation blood thinner drug. Xarelto is unlike its predecessor blood thinners because patients do not require constant monitoring or special diets when using it. These benefits that were not available to patients before and may have contributed to the initial dismissal of the risks associated with the drug. Today, however, these risks are becoming well known because of the thousands of lawsuits filed against the makers of the drug, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer Healthcare. Plaintiffs in these many lawsuits are claiming that Xarelto is one of the most dangerous blood-thinning drugs on the market due to the risk of uncontrollable bleeding it presents to its users. -
Drug Advertisements Under Scrutiny By Xarelto Lawsuit Plaintiffs
May 23, 2016 | Banville Law
TheProductLawyers.com reports on the plaintiffs suing the makers of Xarelto, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer AG, and their reaction to Xarelto commercials. Several commercials have celebrities promoting the benefits of the drug yet they fail to mention the dangerous side effects related to excessive and sometimes fatal bleeding associated with its use. The commercial in question is a promotional piece featuring popular athletes and television celebrities such as NBA star Chris Bosh, Saturday Night Live personality Kevin Nealon, golf legend Arnold Palmer and NASCAR hit Brian Vickers. Each of these celebrity spokespersons talks about the benefits of the drug, but ignore any mention of the dangerous risks that many patients taking the drug face. Plaintiffs in the over 3,000 cases have a much different view of the drug than that being represented in the commercials. -
Xarelto Lawsuit Plaintiff Claims Drug Caused Lasting Medical Problems
May 26, 2016 | Banville Law
TheProductLawyers.com reports on Xarelto, a blood thinner drug approved by the U.S. Food and Drug Administration (FDA) designed to treat patients with a variety of medical conditions such as atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism. It is also used in patients that have undergone surgical procedures such as hip and knee replacement in order to prevent blood clots. -
Ohio Couple Files Xarelto Lawsuit Alleging Drug Caused Internal Bleeding
May 26, 2016 | Banville Law
TheProductLawyers.com reports on the number of lawsuits that have been filed against the manufacturers of the blood-thinning drug Xarelto, JanssenPharmaceuticals, a subdivision of the Johnson and Johnson Corporation, and Bayer AG. There have been more than 3,400 suits filed from across the United States since the U.S. Food and Drug Administration (FDA) approved the drug in 2011. Plaintiffs claim that the anticoagulant puts patients at a higher risk of experiencing dangerous and life-threatening bleeding episodes. Many of them have proven fatal. The plaintiffs in these cases also claim that the makers of the drug did not fully disclose to the public and to medical professionals prescribing the drug of the dangerous side effects that could ensue from taking it. -
Xarelto Lawsuit Plaintiffs Note Celebrity Endorsement Of Drug
May 27, 2016 | Banville Law
TheProductLawyers.com reports on the public relations and advertising campaign undertaken by Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer AG, in regard to the blood-thinning drug Xarelto. The makers of Xarelto have retained celebrities and famous athletes to endorse the benefits of Xarelto but failed to sufficiently state the potentially dangerous risks involved with taking the drug according to several plaintiffs who have filed suit against the drug manufacturers. -
Xarelto Lawsuit Plaintiff Claims Drug Manufacturers Responsible For Husband's Death
May 27, 2016 | Banville Law
TheProductLawyers.com reports the U.S. Food and Drug Administration (FDA) approval of Xarelto in 2011, which at the time was launched as a new-generation blood thinner drug. Xarelto is unlike its predecessor blood thinners because patients do not require constant monitoring or special diets when using it. -
Life-Threatening Side Effects Prompt Xarelto Lawsuit Filing
May 25, 2016 | Legal Examiner
By Laurence Banville
TheProductLawyers.com reports on an Ohio couple who have filed a lawsuit against the makers of Xarelto, a blood-thinning drug designed to treat patients afflicted with atrial fibrillation, pulmonary embolism, and deep vein thrombosis (DVT), as well as for those who have undergone hip and knee replacement surgery. The couple’s suit alleges the manufacturers, Janssen Pharmaceuticals, a division of the Johnson and Johnson Corporation, and Bayer AG, failed to properly inform the public and medical professionals about the risks involved with taking Xarelto. -
Janssen, Bayer Face Xarelto Wrongful Death Lawsuit
May 22, 2016 | Righting Injustice
By Jennifer Walker-Journey
The daughter of an Ohio man has filed a wrongful death lawsuit against the makers of the blood thinner Xarelto. -
Xarelto Lawsuit Filed After Maryland Woman Dies
May 24, 2016 | Top Class Actions
By Joanna Szabo
A number of Louisiana plaintiffs recently filed a joint Xarelto lawsuit against Janssen Pharmaceuticals, alleging that the drug caused severe Xarelto side effects including uncontrollable internal bleeding. -
22 Plaintiffs File Lawsuit Over Dangerous Xarelto Side Effects
May 26, 2016 | Top Class Actions
By Laura Schultz
A new Xarelto side effects lawsuit was collectively filed in federal court against pharmaceutical manufacturers Janssen Research and Development and Bayer Healthcare Pharmaceuticals. -
Xarelto Lawsuit Filed Over Life-Threatening Bleeding Problems from Anticoagulant
May 27, 2016 | About Lawsuits
By Irvin Jackson
According to allegations raised in a recent product liability lawsuit filed against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals subsidiary, side effects of Xarelto caused life-threatening bleeding problems for a woman who received the controversial new-generation anticoagulant. -
Xarelto Litigation Progresses Amid Growing Sales
May 26, 2016 | Drug Watch
By Michelle Llamas
Johnson & Johnson and Bayer’sblockbuster blood thinner Xareltocontinues to post impressive sales numbers. But, the number of people filing lawsuits against the drug’s makers is also growing. Thousands of plaintiffs claim J&J and Bayer hid the danger of uncontrolled bleeding and engaged in misleading advertising. -
Man Files Xarelto Gastrointestinal Bleeding Lawsuit
May 24, 2016 | Xarelto Lawsuit
By Miller Legal LLP
An Illinois man recently joined roughly 4,500 other plaintiffs who have filed federal lawsuits based on claims that they suffered serious injury or the wrongful death of a loved one due to unwarned-of Xarelto side effects. -
Why Does Xarelto Use Celebrity Endorsements?
May 27, 2016 | NastlLaw News
By NastLaw LLC
Have you ever seen the advertisement on TV for Xarelto? The one with hall-of-fame golfer, Arnold Palmer, sinking a hole in one with the rest of his celebrity cast, Chris Bosh, Brian Vickers and Kevin Nealon.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
-
Widow Files Xarelto Bleeding Lawsuit After Husbands Death
May 25, 2016 | Banville Law
May 25, 2016 – /PressAdvantage/ – TheProductLawyers.com reports on the death of a Xarelto user who suffered a subdural hemorrhage due to uncontrollable internal bleeding that doctors were unable to stop. His widow alleges the fatal bleed was caused by taking Xarelto, a blood-thinning drug manufactured by Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer Healthcare.
The widow has filed a lawsuit against the makers of the drug claiming that they did not sufficiently warn consumers about the dangerous bleeding risks associated with the drug. Her case was originally filed in the State of Florida but is now part of the 2,800 cases that have been consolidated by a decision of the U.S. Judicial Panel on Multidistrict Litigation (JPML). The multidistrict litigation (MDL 2592) cases are being overseen by Judge Eldon Fallon in a federal court in the Eastern District of Louisiana.
In addition to the cases encompassed in the MDL, there are 550 more cases that the Court of Common Pleas in Philadelphia, Pennsylvania has consolidated in a mass tort program.
The U.S. Food and Drug Administration approved and released Xarelto to the consumer market in 2011. It was at the time touted as a new-generation blood-thinning drug since it was unlike its predecessor drugs in that patients no longer had to follow strict, special diets nor did they have to be continually monitored by medical professionals. Unfortunately, this excitement over the drug and its benefits may have initially overshadowed the dangerous risks associated with it. Today, however, many plaintiffs have filed lawsuits against the manufacturers of the drug alleging that it has dangerous and life-threatening risks to patients taking it. The FDA seems to concur since it has issued two black box warnings against Xarelto. Black box warnings are extremely serious and many times are a precursor to the drug being taken off the market.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
###
Contact TheProductLawyers.com:
Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023http://www.wave3.com/story/32067887/widow-files-xarelto-bleeding-lawsuit-after-husbands-death
-
Xarelto Lawsuit Plaintiff Claims Drug Manufacturers Responsible For Husbands Death
May 24, 2016 | Banville Law
May 24, 2016 – /PressAdvantage/ – TheProductLawyers.com reports the U.S. Food and Drug Administration (FDA) approval of Xarelto in 2011, which at the time was launched as a new-generation blood thinner drug. Xarelto is unlike its predecessor blood thinners because patients do not require constant monitoring or special diets when using it. These benefits that were not available to patients before and may have contributed to the initial dismissal of the risks associated with the drug. Today, however, these risks are becoming well known because of the thousands of lawsuits filed against the makers of the drug, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer Healthcare. Plaintiffs in these many lawsuits are claiming that Xarelto is one of the most dangerous blood-thinning drugs on the market due to the risk of uncontrollable bleeding it presents to its users.
Xarelto is now the focus of concern in an excess of 2,800 federally-filed lawsuits from across the United States along with 550 or more additional cases in a mass tort program created by an action of the Court of Common Pleas in Philadelphia, Pennsylvania.
One lawsuit in particular filed by a south Florida resident on behalf of her deceased husband, alleges the manufacturers of the drug failed to sufficiently warn consumers of the serious bleeding risks associated with Xarelto. The plaintiff is claiming that her husband’s use of Xarelto to lessen the threat of having a stroke due to his atrial fibrillation caused his untimely death. He suffered an instance of uncontrollable internal bleeding that doctors could not stop while he was using the drug. This case was eventually transferred to the Eastern District of Louisiana with the U.S. Judicial Panel’s consolidation order which is now being overseen by the Honorable Judge Eldon Fallon.
An action by the U.S. Food and Drug Administration (FDA) has given plaintiffs even more ammunition in their legal battle against the manufacturers of Xarelto. The agency has issued two black box warnings which are the harshest warnings possible prior to a product being fully removed from the market.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
###
Contact TheProductLawyers.com:
Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023http://www.kiiitv.com/story/32057077/xarelto-lawsuit-plaintiff-claims-drug-manufacturers-responsible-for-husbands-death
-
Drug Advertisements Under Scrutiny By Xarelto Lawsuit Plaintiffs
May 23, 2016 | Banville Law
TheProductLawyers.com reports on the plaintiffs suing the makers of Xarelto, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer AG, and their reaction to Xarelto commercials. Several commercials have celebrities promoting the benefits of the drug yet they fail to mention the dangerous side effects related to excessive and sometimes fatal bleeding associated with its use. The commercial in question is a promotional piece featuring popular athletes and television celebrities such as NBA star Chris Bosh, Saturday Night Live personality Kevin Nealon, golf legend Arnold Palmer and NASCAR hit Brian Vickers. Each of these celebrity spokespersons talks about the benefits of the drug, but ignore any mention of the dangerous risks that many patients taking the drug face. Plaintiffs in the over 3,000 cases have a much different view of the drug than that being represented in the commercials.
In a disturbing development, the U.S. Food and Drug Administration (FDA) has given Xarelto two black box warnings since the agency approved the new-generation blood-thinning drug. A black box warning is a very severe and harsh warning that a product can get before it is pulled from the market entirely.
Since its release on the market, Xarelto has become the focus of many federal courtroom proceedings across the United States. Over 2,800 cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) because all the cases involved the same defendants, Janssen, and Bayer, and had the same allegations related to excessive bleeding levied in all of the court filings. The multidistrict litigation (MDL) will be overseen by the Honorable Judge Eldon Fallon of the Eastern District of Louisiana.
While these plaintiffs await their day in court, another 550 have been consolidated in a mass tort program in Philadelphia, PA. It is expected that more cases will be added as the litigation continues.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
-
Xarelto Lawsuit Plaintiff Claims Drug Caused Lasting Medical Problems
May 26, 2016 | Banville Law
May 26, 2016 – /PressAdvantage/ – TheProductLawyers.com reports on Xarelto, a blood thinner drug approved by the U.S. Food and Drug Administration (FDA) designed to treat patients with a variety of medical conditions such as atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism. It is also used in patients that have undergone surgical procedures such as hip and knee replacement in order to prevent blood clots.
Since its initial approval, however, the FDA has issued two black box warnings for Xarelto. Such warnings could result in the drug’s complete removal from the market as these warnings are the most strict type of warning that can be given to a product.
The FDA’s concerns are verified by the filing of more than 3,400 lawsuits in federal courts all across the United States by plaintiffs alleging that the use of the anticoagulant placed patients using it at a much higher risk of instances of severe and uncontrollable bleeding, many of which have also proven to be fatal. Additionally, plaintiffs are claiming that the manufacturers, Bayer AG and Janssen Pharmaceuticals, a division of the Johnson and Johnson Corporation, did not adequately inform patients and medical professionals of the risks associated with the drug.
One particular lawsuit was filed by a married couple in Ohio, who claim that the wife was prescribed Xarelto to treat her atrial fibrillation, a heart condition which increases the risk of stroke. The plaintiffs claim that only after 2 months of starting to take Xarelto she experienced a life-threatening gastrointestinal bleeding occurrence, anemia, and other unspecified injuries, as per the couple’s court paperwork. The couple is seeking over $150,000 in compensatory damages to cover medical bills that have been and will be incurred and to compensate them for the effects of the bleeding that will be long-term in their duration.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
###
Contact TheProductLawyers.com:
Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023http://www.fox8live.com/story/32078374/xarelto-lawsuit-plaintiff-claims-drug-caused-lasting-medical-problems
-
Ohio Couple Files Xarelto Lawsuit Alleging Drug Caused Internal Bleeding
May 26, 2016 | Banville Law
May 26, 2016 – /PressAdvantage/ – TheProductLawyers.com reports on the number of lawsuits that have been filed against the manufacturers of the blood-thinning drug Xarelto, JanssenPharmaceuticals, a subdivision of the Johnson and Johnson Corporation, and Bayer AG. There have been more than 3,400 suits filed from across the United States since the U.S. Food and Drug Administration (FDA) approved the drug in 2011. Plaintiffs claim that the anticoagulant puts patients at a higher risk of experiencing dangerous and life-threatening bleeding episodes. Many of them have proven fatal. The plaintiffs in these cases also claim that the makers of the drug did not fully disclose to the public and to medical professionals prescribing the drug of the dangerous side effects that could ensue from taking it.
The purpose of Xarelto is to treat patients suffering from deep vein thrombosis (DVT), pulmonary embolism,and atrial fibrillation as well as those who are recovering from hip and knee replacement surgeries.
One of the 3,400 cases was filed by an Ohio couple who allege Xarelto caused the wife to experience a life-threatening gastrointestinal bleeding episode. She was taking Xarelto to minimize the chance of having a stroke because of her atrial fibrillation. The couple’s court documents state that only after two months taking Xarelto, she developed internal bleeding, as well as anemia, and some other unidentified medical conditions. The couple also claims the bleeding has caused the need for long-term medical care and supervision.
It should be noted as well, that the US. Food and Drug Administration (FDA) has made note of these bleeding reports linked to Xarelto use. The agency has issued two black box warnings which are the harshest warnings a product can receive and could cause it to be totally removed from the market.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
###
Contact TheProductLawyers.com:
Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023http://www.wrcbtv.com/story/32078362/ohio-couple-files-xarelto-lawsuit-alleging-drug-caused-internal-bleeding
-
Xarelto Lawsuit Plaintiffs Note Celebrity Endorsement Of Drug
May 27, 2016 | Banville Law
TheProductLawyers.com reports on the public relations and advertising campaign undertaken by Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer AG, in regard to the blood-thinning drug Xarelto. The makers of Xarelto have retained celebrities and famous athletes to endorse the benefits of Xarelto but failed to sufficiently state the potentially dangerous risks involved with taking the drug according to several plaintiffs who have filed suit against the drug manufacturers.
The commercial in question features Saturday Night Live star Kevin Nealon, golf legend Arnold Palmer, NBA star Chris Bosh, and NASCAR driver Brian Vickers. Each of these celebrities endorses the virtues of Xarelto and provide information about the drug but fail to mention risks such as excessive bleeding which could cause death.
There have been thousands of lawsuits filed against Janssen and Bayer since the drug was released on the market with over 2,800 being consolidated into a multidistrict litigation (MDL) in Louisiana under the oversight of the Honorable Judge Eldon Fallon. Another 550 cases have been consolidated in a mass tort program in Philadelphia, PA. The plaintiffs in these cases have a much different view of the drug than that expressed by the celebrity spokespersons in the Xarelto commercial. Many plaintiffs are questioning the tactics of the manufacturers and feel the ad is very misleading as they allege it puts users at risk of severe uncontrollable bleeding.
It should also be noted that the U.S. Food and Drug Administration (FDA) has questioned the safety of the drug as well in its issuance of two black box warnings for the drug since the agency approved it for release on the market. Black box warnings are ominous and do not portend well for a product since these warnings come at a point when it is potentially about to be pulled from the market.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.digitaljournal.com/pr/2950662#ixzz49t7t4riU
-
Xarelto Lawsuit Plaintiff Claims Drug Manufacturers Responsible For Husband's Death
May 27, 2016 | Banville Law
TheProductLawyers.com reports the U.S. Food and Drug Administration (FDA) approval of Xarelto in 2011, which at the time was launched as a new-generation blood thinner drug. Xarelto is unlike its predecessor blood thinners because patients do not require constant monitoring or special diets when using it. These benefits that were not available to patients before and may have contributed to the initial dismissal of the risks associated with the drug. Today, however, these risks are becoming well known because of the thousands of lawsuits filed against the makers of the drug, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer Healthcare. Plaintiffs in these many lawsuits are claiming that Xarelto is one of the most dangerous blood-thinning drugs on the market due to the risk of uncontrollable bleeding it presents to its users.
Xarelto is now the focus of concern in an excess of 2,800 federally-filed lawsuits from across the United States along with 550 or more additional cases in a mass tort program created by an action of the Court of Common Pleas in Philadelphia, Pennsylvania.
One lawsuit in particular filed by a south Florida resident on behalf of her deceased husband, alleges the manufacturers of the drug failed to sufficiently warn consumers of the serious bleeding risks associated with Xarelto. The plaintiff is claiming that her husband's use of Xarelto to lessen the threat of having a stroke due to his atrial fibrillation caused his untimely death. He suffered an instance of uncontrollable internal bleeding that doctors could not stop while he was using the drug. This case was eventually transferred to the Eastern District of Louisiana with the U.S. Judicial Panel's consolidation order which is now being overseen by the Honorable Judge Eldon Fallon.
An action by the U.S. Food and Drug Administration (FDA) has given plaintiffs even more ammunition in their legal battle against the manufacturers of Xarelto. The agency has issued two black box warnings which are the harshest warnings possible prior to a product being fully removed from the market.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.digitaljournal.com/pr/2950784#ixzz49ta5muuL
-
Life-Threatening Side Effects Prompt Xarelto Lawsuit Filing
May 25, 2016 | Legal Examiner
By Laurence Banville
TheProductLawyers.com reports on an Ohio couple who have filed a lawsuit against the makers of Xarelto, a blood-thinning drug designed to treat patients afflicted with atrial fibrillation,pulmonary embolism, and deep vein thrombosis (DVT), as well as for those who have undergone hip and knee replacement surgery. The couple’s suit alleges the manufacturers, Janssen Pharmaceuticals, a division of the Johnson and Johnson Corporation, and Bayer AG, failed to properly inform the public and medical professionals about the risks involved with taking Xarelto.
Ohio Couple File Suit
In the Ohio couple’s court documents, they state that the wife was given Xarelto as a treatment for her atrial fibrillation and, as a result, had suffered a gastrointestinal bleed and anemia only two months after beginning her treatment. Because of this internal bleeding, the couple is seeking over $150,000 in compensatory damages to cover both current and future medical bills since she is now additionally being treated for other long-term medical conditions related to the bleeding.
FDA Warnings
Xarelto was approved for release on the market by the U.S. Food and Drug Administration (FDA) in 2011. However, since the agency’s initial approval, it has issued Xarelto two black box warnings. A black box warning is a very harsh, and usually portends a possible removal of a product from the consumer market.
Consolidation Of Lawsuits
In addition to the Ohio couple, there have been numerous other lawsuits filed in excess of 3,400 and from all across America. In most, if not all of the cases, the plaintiffs uniformly allege that the anticoagulant places patients at a much higher risk for instances of dangerous, and sometimes fatal bleeding. Of the lawsuits filed over 2,800 of the cases have been consolidated into a multidistrict litigation numbered 2592, while another group of over 550 lawsuits has been consolidated into a mass tort program by the Court of Common Pleas in Philadelphia, PA.
http://newyorkcity.legalexaminer.com/fda-prescription-drugs/life-threatening-side-effects-prompt-xarelto-lawsuit-filing/
-
Janssen, Bayer Face Xarelto Wrongful Death Lawsuit
May 22, 2016 | Righting Injustice
By Jennifer Walker-Journey
The daughter of an Ohio man has filed a wrongful death lawsuitagainst the makers of the blood thinner Xarelto.
Michelle Clark, on behalf of her deceased father, Clarence Mason, filed the complaint in the U.S. District Court for the Eastern District of Louisiana. The lawsuit names Johnson & Johnson’s Janssen Pharmaceuticals, Bayer Healthcare, and their related companies.
According to the complaint, Clarence took Xarelto as prescribed from Dec. 26, 2013, until August 2014. In April 2014, the man suffered gastrointestinal bleeding, which caused him pain and suffering, disability, disfigurement, mental anguish, and loss of the ability to enjoy life. He was hospitalized, required medical and nursing treatment, and ultimately died from his injuries.
Clark claims that the drug companies are responsible for her father’s death because they allegedly designed, researched, manufactured, tested, advertised, promoted, marketed, distributed, and soldXarelto. The lawsuit also claims the companies failed to properly investigate, research, study and define the risks associated with use of the drug, and failed to adequately warn doctors or patients of the risks. The lawsuit also alleges that the drug companies failed to disclose the need for dose adjustments or provide adequate instructions for safe use of Xarelto.
Clark’s lawsuit is one of hundreds involving Xarelto bleeding risks. The first bellwether cases are scheduled to begin in early 2017 in Louisiana with two others slated through the end of 2017.
Xarelto is a blood thinner that is used to prevent strokes in patients with atrial fibrillation, prevent or treat deep vein thrombosis and pulmonary embolism, and to prevent blood clots in patients who have recently undergone hip or knee replacement surgery.
http://www.rightinginjustice.com/news/2016/05/22/janssen-bayer-face-xarelto-wrongful-death-lawsuit/
-
Xarelto Lawsuit Filed After Maryland Woman Dies
May 24, 2016 | Top Class Actions
By Joanna Szabo
A number of Louisiana plaintiffs recently filed a joint Xarelto lawsuit against Janssen Pharmaceuticals, alleging that the drug caused severe Xarelto side effects including uncontrollable internal bleeding.
One Maryland plaintiff’s Xarelto side effects were allegedly so severe that she died from the complications. Joann B., deceased, is represented in this lawsuit by her executor.
According to the Xarelto lawsuit, Joann began taking Xarelto as a blood clot treatment in January 2011, and stopped taking it in May 2013 when she suffered from a fatal pulmonary hemorrhage.
The Xarelto lawsuit alleges that Janssen Pharmaceuticals either knew or should have known about the severe and possibly fatal side effects of their drug.
Because the company failed to adequately warn the public and the medical community about these complications, Joann’s lawsuit alleges, Janssen is responsible for her injuries and death.
Xarelto Side Effects
Xarelto (rivaroxaban), a popular blood clot treatment drug, has been the target of a number of Xarelto lawsuits across the country. The lawsuits are filed against Xarelto’s manufacturer, Janssen Pharmaceuticals, which is a subsidiary of Johnson & Johnson.
Xarelto is a blood thinner often prescribed to prevent blood clotting. Blood clots can be dangerous or even fatal, so blood clot treatment is a common approach to helping patients who suffer from a number of conditions in which blood clots can be especially dangerous.
Patients who suffer from atrial fibrillation (irregular heartbeat), pulmonary embolism (blood clots in the lungs), or deep vein thrombosis (blood clots deep inside the body) are particularly likely to require blood clot treatment such as Xarelto.
Most patients who develop Xarelto side effects only suffer from mild complications that go away on their own, but some patients experience much more dangerous side effects, including excessive bleeding.
Excessive bleeding can be dangerous or even fatal.
Xarelto Lawsuits
Xarelto lawsuits claim that Janssen Pharmaceuticals either knew or should have known about the excessive bleeding risks linked with Xarelto, but the company failed to adequately warn the public and the medical community about these complications.
Xarelto lawsuits further claim that, despite this knowledge, Janssen continued to market Xarelto as completely safe and effective, diminishing possible concerns over severe side effects.
A Xarelto lawsuit cannot negate the pain and suffering of a patient who experiences severe Xarelto side effects such as excessive bleeding. However, a successful Xarelto lawsuit can help with the financial expenses incurred by medical bills and lost wages.
If you or someone you love has experienced severe Xarelto side effects, including excessive internal bleeding, after using Xarelto, you may be able to file a Xarelto lawsuit against Janssen.
This joint Xarelto lawsuit was filed on multiple counts, including defective design, failure to warn, negligence, and fraud.
The Xarelto Lawsuit is filed within the larger Xarelto multidistrict litigation, In Re Xarelto Products Liability Litigation, MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/335801-xarelto-lawsuit-filed-maryland-woman-dies/
-
22 Plaintiffs File Lawsuit Over Dangerous Xarelto Side Effects
May 26, 2016 | Top Class Actions
By Laura Schultz
A new Xarelto side effects lawsuit was collectively filed in federal court against pharmaceutical manufacturers Janssen Research and Development and Bayer Healthcare Pharmaceuticals.
The lawsuit, filed jointly by 22 plaintiffs, alleges that the company violated consumer protection laws by failing to warn consumers about Xarelto side effects, including internal bleeding.
One of the plaintiffs, Betty D., a resident of Louisiana, took Xarelto between June 2015 to July 2015. In July, Betty suffered a gastrointestinal bleed. According to the lawsuit Betty’s internal bleeding was a direct result of taking Xarelto.
Charles B. is another plaintiff who joined the Xarelto lawsuit. Charles took Xarelto between January and May 2015. In May of 2015, Charles suffered internal bleeding similar to Betty.
Several of the other plaintiffs who joined the lawsuit also suffered from gastrointestinal bleeds. Some of the other plaintiffs also suffered from things like angina, bloody stool, hermarthrosis, and several other serious internal bleeding Xarelto side effects.
The plaintiffs are bringing claims against the pharmaceutical manufacturers for violating consumer protection laws. The lawsuit is bringing actions for negligence, breach of warranty, and products liability.
What is Xarelto?
Xarelto is a popular blood thinning medication that doctors prescribe to patients who are at risk of developing stroke or systemic embolism.
Xarelto received FDA approval back in July 2011. The medication was first approved to treat deep vein thrombosis and pulmonary embolism.
Xarelto has been advertised as a superior anticoagulant compared to the more traditional and established blood thinner Warfarin.
Xarelto Side Effects: Internal Bleeding
While all blood thinning medications are associated with internal bleeding side effects Xarelto has no known antidote. Because of this, patients are at a serious risk of uncontrolled internal bleeding.
Patients who take the more traditional blood thinner Warfarin can feel comfort knowing that Warfarin has a known antidote. Patients who experience uncontrolled bleeding can be given a dose of vitamin K to counteract the blood thinning effects of the medication.
Patients who have experienced internal bleeding while taking Xarelto may be able to bring their own lawsuit against the pharmaceutical manufacturer. Successful plaintiffs may receive compensation for their pain and suffering.
The Xarelto Side Effects Lawsuit is Case No. 2:16-cv-6535 in the United States District Court in the Eastern District of Louisiana.
According to the Xarelto lawsuit, the studies that back these advertising statements were performed in a negligent and flawed manner. In fact, the US FDA found the studies so flawed with rampant violations that they were deemed unreliable.
According to the lawsuit, the Rocket AF study that compared the effectiveness and risks of both Warfarin and Xarelto was one of the worst reported clinical studies in the history of clinical trial studies.
Some medical professionals have also voiced concern over the set dosage. Dr. Nissen who testified at an FDA advisory meeting stated a concern that the dose was selected for marketing reasons rather than the health of patients.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/335990-22-plaintiffs-file-lawsuit-dangerous-xarelto-side-effects/
-
Xarelto Lawsuit Filed Over Life-Threatening Bleeding Problems from Anticoagulant
May 27, 2016 | About Lawsuits
By Irvin Jackson
According to allegations raised in a recent product liability lawsuit filed against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals subsidiary, side effects of Xarelto caused life-threatening bleeding problems for a woman who received the controversial new-generation anticoagulant.
The case joins a growing number of Xarelto lawsuits filed on behalf of individuals who have experienced similar problems with uncontrollable bleeding, with more than 5,250 cases currently pending as part of a federal multidistrict litigation (MDL), which is centralized before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana to reduce duplicative discovery, avoid conflicting pretrial rulings and serve the convenience of witnesses, parties and the courts.
While all blood thinners carry a risk of bleeding, the cases raise similar allegations that Bayer and Janssen failed to warn consumers and doctors about the potential Xarelto bleeding problems, and the fact that the anticoagulant had no reversal agent to allow doctors to quickly stop bleeding that may develop while using the drug.
A complaint (PDF) filed this week by Texas resident Ruth Ramsoondar is one of the latest to join the litigation, indicating that she suffered a life-threatening bleeding event in June 2014, after she began using Xarelto in April 2014. She survived the bleed, but indicates that she has been left with permanent injuries, pain, suffering and severe emotional distress.
Like other lawsuits pending nationwide, Ramsoondar alleges that the drug makers failed to conduct adequate testing for bleeding problems, or else they would have known Xarelto bleeds were difficult, and sometimes impossible, to stop.
“Prior to applying for and obtaining approval for Xarelto, Defendants knew or should have known that consumption of Xarelto was associated with and/or would cause the induction of life-threatening bleeding, and Defendants possessed at least one clinical scientific study, which evidence Defendants knew or should have known was a signal that life-threatening bleeding risk needed further testing and studies prior to its introduction to the market,” the lawsuit states.
Ramsoondar is pursuing claims of negligence, strict product liability, breach of warranty, fraudulent misepresentation, fraudulent concealment, negligent misrepresentation, fraud and deceit, and loss of consortium on behalf of her husband, Ramjit Ramsoondar. The lawsuit seeks both compensatory and punitive damages.
Xarelto Bleeding Problems
Xarelto (rivaroxoaban) was introduced in 2011 as a new-generation anticoagulant, designed to replace for Coumadin (warfarin), which has been the go-to anticoagulant treatment for decades.
The drug is part of a new class of medications designed to avoid blood clots among individuals at risk for deep vein thrombosis or pulmonary embolism, which have been promoted as easier to use than warfarin. However, since the drugs have hit the market, there have been a large number of reports involving severe and sometimes fatal bleeding problems with Xarelto and other members of this new class, including Pradaxa and Eliquis.
Each of the lawsuits involved in the Xarelto MDL raise nearly identical allegations, indicating that the drug carries a high risk of severe bleeds, and that information was withheld from the medical community about the lack of a safe and effective reversal agent for Xarleto to allow doctors to quickly stop the blood thinning effects of the drug.
While the side effects of warfarin can be quickly reversed with a widely known antidote if bleeding occurs, there was no Xarelto reversal agent when the drug was introduced. Plaintiffs allege that the drug makers failed to adequately warn doctors about the lack of an antidote.
Similar claims were raised in the litigation over Pradaxa, which is a different medication that is part of the same new class of novel oral anticoagulants.
More than 4,000 Pradaxa lawsuits were ultimately filed by users of that drug who suffered bleeding injuries over that medication, which was introduced about one year before Xarelto. Following several years of litigation, the manufacturer of that medication ultimately agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
As Xarelto injury lawyers continue to review potential cases for individuals and families nationwide, it is expected that the number of lawsuits involved in the MDL will continue to grow over the coming months, and will far exceed those involved in the Pradaxa litigation.
Judge Fallon has scheduled a series of early Xarleto bellwether trials in the MDL, which are expected to begin in February 2017. While the outcomes of these early trial dates will not be binding on other claims, they may help the parties negotiate Xarelto settlements that could avoid the need for thousands of individual cases to go before juries nationwide.
- See more at: http://www.aboutlawsuits.com/xarelto-lawsuits-bleeding-problems-anticoagulant-101933/#sthash.z6y1oaU5.dpuf
-
Xarelto Litigation Progresses Amid Growing Sales
May 26, 2016 | Drug Watch
By Michelle Llamas
Johnson & Johnson and Bayer’sblockbuster blood thinner Xareltocontinues to post impressive sales numbers. But, the number of people filing lawsuits against the drug’s makers is also growing. Thousands of plaintiffs claim J&J and Bayer hid the danger of uncontrolled bleeding and engaged in misleading advertising.
Xarelto is still the most prescribed drug in its class in the U.S. and will remain the top drug well into 2022 in Europe, EvaluatePharma analysts report. Though sales remain strong, some experts still worry about heavy bleeding side effects caused by the drug. In some cases, uncontrolled bleeding can be fatal.
The bleeding side effects led to a surge in lawsuits.
“The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases,” J&J said in its 2015 Annual report.
As of May 2016, there were 5,260 claims pending in federal court in the Eastern District of Louisiana before Judge Eldon E. Fallon. Plaintiffs claim a number of side effects were caused by Xarelto, including strokes, blood clots and hemorrhages.
Bellwether Cases Selected
Out of over 5,000 cases, Judge Fallon gathered 40 into a preliminary pool for bellwether trials in January 2016. Plaintiff and defendant attorneys choose these cases as the most representative of the entire group. Bellwethers can help predict how cases are like to proceed.
According to court documents, Judge Fallon announced the first 4 cases set for trial from this initial group. The trials are set to being in early 2017. The judge scheduled the first two for February 6 and March 13. The second pair will proceed on April 24 and May 30.
Ellen Relkin, a member of the plaintiff’s steering committee for the Louisiana MDL, says that a big problem with Xarelto is its “one-size-fits-all” design.
“[A] problem with the medication is it has what is called ‘a low therapeutic index.’ In other words, it can be safe at a certain point and dangerous within a very close range,” Relkin previously told Drugwatch. “Someone can be 110 pounds or 200 pounds, old or young [and] with varying kidney functions and get the same dose and have a very different impact.”
Xarelto Claims May Follow in Pradaxa’s Example
While experts say it is too early to predict the future of thousands of Xarelto claims, attorneys say these claims may follow a similar path to Pradaxa claims.
Pradaxa, a similar blood thinner manufactured by Boehringer Ingelheim, faced thousands of lawsuits for uncontrolled bleeding. In 2014, the drug maker settled all state and federal lawsuits for $650 million.
Before the Xarelto cases come close to settling, attorneys say the Xarelto multidistrict litigation will continue to grow.
“I expect to see an increase in filings over the next month or two given the media attention caused by The New York Times’ recent report, but on the whole this is now a stable mass tort that is reasonably well known,” Philadelphia attorney Max Kennerly told Forbes.
Kennerly is involved in the group of Philadelphia cases, which is separate from the federal MDL in Louisiana.
“Philly has just set up a deposition protocol [in March], so they are some time away from getting near trial-ready. I would expect a Philly bellwether [trial] in summer 2017 or later,” he said.
https://www.drugwatch.com/2016/05/26/xarelto-bellwether-trial-set/
-
Man Files Xarelto Gastrointestinal Bleeding Lawsuit
May 24, 2016 | Xarelto Lawsuit
By Miller Legal LLP
An Illinois man recently joined roughly 4,500 other plaintiffs who have filed federal lawsuits based on claims that they suffered serious injury or the wrongful death of a loved one due to unwarned-of Xarelto side effects.
Austin Foster filed his Xarelto lawsuit in the U.S. District Court for the Eastern District of Louisiana on April 13, naming multiple pharmaceutical companies as defendants. Here, he claims that he suffered severe gastrointestinal bleeding leading to physical, emotional, and financial damages as a result of Xarelto side effects. He also claims that the makers of Xarelto failed to conduct adequate testing to ensure the safety of the drug and also failed to provide adequate warnings of Xarelto side effects of which they were aware or should have been aware.
Mr. Foster began to take Xarelto in April 2014. In September 2014, he was hospitalized for severe gastrointestinal bleeding. This caused him to incur hefty medical expenses, suffer physical and emotional pain and anguish, and also caused him to suffer diminished enjoyment of life as well as other damages.
Since December 2014, all Xarelto lawsuits filed in federal courts have been centralized for coordinated pretrial proceedings in a multidistrict litigation (MDL) before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana. These lawsuits have been consolidated because they are all based on common allegations that plaintiffs were not warned of serious Xarelto side effects, and many of them are based on claims of severe internal bleeding injuries.
In Xarelto lawsuits, many plaintiffs have claimed that the makers of this drug not only failed to warn of the risk of Xarelto internal bleeding, but that they also failed to inform patients that there is no reversal agent to stop Xarelto bleeding. When Xarelto was first introduced, it was promoted as a safer and more convenient alternative to warfarin (Coumadin), the go-to anticoagulant for decades. Xarelto was believed by many to be more convenient than warfarin because patients taking the new blood thinner would not require regular blood monitoring as is necessary for warfarin patients. However, in recent years many experts have stated that regular blood monitoring may have helped prevent some Xarelto bleeding injuries. Additionally, when patients taking warfarin develop a serious bleed a doctor can induce clotting with a dose of Vitamin K, butthere is no such antidote for Xarelto bleeding.
It is expected that the first jury trials in the Xarelto MDL will begin early in 2017. If a significant number of claims are not settled before trial, it may become necessary for Judge Fallon to remand them back to state courts so that individual trials may take place. Even as attorneys from both sides prepare early cases for this MDL, plaintiffs continue to come forward in demand of compensation for their suffering and damages as a result of Xarelto side effects. If you believe you may be entitled to compensation for your suffering due to Xarelto side effect, pleasecontact us for a free legal consultation with an experienced personal injury attorney.
http://www.xareltolawsuit.com/news/man-files-xarelto-gastrointestinal-bleeding-lawsuit/
-
Why Does Xarelto Use Celebrity Endorsements?
May 27, 2016 | NastlLaw News
By NastLaw LLC
Have you ever seen the advertisement on TV forXarelto? The one with hall-of-fame golfer, Arnold Palmer, sinking a hole in one with the rest of his celebrity cast, Chris Bosh, Brian Vickers and Kevin Nealon.
It shows them all enjoying a beautiful day, uninhibited by the status of their health because they know they can “count on Xarelto” to keep them moving.
But why are the manufacturers of Xarelto paying millions of dollars for television ads with a star studded cast?
Research shows that brands and corporations can benefit from using celebrity endorsements. A study done in July 2011 by Harvard Business School professor Anita Elberse and Barclays Capital Analyst Jerone Verleuni found that, on average, celebrity endorsements can increase a company’s sales by $10 million annually and provide a 0.25% increase in stock price.
Xarelto’s manufacturers hope that those needing blood clot treatment medication ask for Xarelto because it’s something they saw their “idols” endorse on TV.
After seeing the commercials, when you think of Xarelto you almost always think of Arnold Palmer and a golf course. Without knowing Xarelto is a blood thinner, you hear the brand’s name and associate Mr. Palmer with the medication.
Associating Xarelto with this group of celebrities helps Bayer (the manufacturer) because not only do they reach the golfers of the world, but now the entertainment industry, basketball lovers, and NASCAR fanatics of the country.
Of course, Xarelto is not the only drug of its kind. There is Warfarin, Eliquis, and Pradaxa. Many compare Xarelto to Warfarin, the blood thinning medication that has been on the market for the past 60 years. Warfarin, although popular, can discourage patients from using it due to its strict dietary restrictions and mandatory blood monitoring.
The problem with these marketing tactics is that they encourage patients to ask for a product that is more dangerous than its competitors.
Xarelto’s first year on the market was in 2012. During that time-frame a total of 2,081 serious adverse event (SAE) reports were filed that were Xarelto-related. An estimated 151 deaths were a result from Xarelto, while only 56 deaths were associated with Warfarin.
Not only did Xarelto see a 3x higher risk of a SAE than Warfarin, but there is no antidote to stop serious bleeding Xarelto can cause. With no mandatory blood monitoring, it is hard to catch when serious bleeding is occurring.
The real question is, do these endorsers even know about the severe health risks and issues surrounding Xarelto? Probably not. But just because they may not know of severe risks does not mean there are not any.
Chances are they have yet to experience any severe side effects the medicine could cause. But due to the lack of blood monitoring, how would anyone know if they are at risk for aside effect?
Celebrities aren’t invincible. They have the same chance of having side effects just as the “average Joe” does.
Visit NastLaw.com/xarelto to learn more about the dangers of Xarelto. We believe that the manufacturers of this drug did not provide adequate warning about the potential dangers for serious bleeding. Making blood tests mandatory for Xarelto users would help reduce the severe risks.
So next time you see your good ‘ole friend Arnold Palmer putting a few, trying to sell you on taking Xarelto, do your research. Know the risks you face, and learn more about the company trying to sell you the drug.
https://nastlaw.com/xarelto-using-celebrity-endorsements/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
Add recipients
Suggested